Egetis Therapeutics
Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities. The Company's lead product, EMCITATE® (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and now in the United States. Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.For more information, visit egetis.com and follow the Company on LinkedIn.Content by Egetis Therapeutics
| 6 min read
Six studies backed tiratricol's FDA approval for peripheral thyrotoxicosis in MCT8 deficiency, an ultra-rare pediatric thyroid transport disorder
Page 1 of 1 - 1 Total Items
